Author

M. Zinda

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:genetic perturbation / CRISPR· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 1 Research Focus:synaptic & neural circuits· 1

Frequent Co-Authors

A. Veloso· 3 shared A. Alvarez-Quilon· 2 shared A. Roulston· 2 shared C. Bernier· 2 shared D. Durocher· 2 shared G. Martino· 2 shared H. Melo· 2 shared J. Desjardins· 2 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Veloso

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Guiding ATR and PARP inhibitor combinations with chemogenomic screens

M. Zimmermann, C. Bernier, B. Kaiser, S. Fournier, L. Li, J. Desjardin, A. Skeldon, V. Rimkunkas, A. Veloso, J. T. Young, A. Roulston, M. Zinda

This study identifies genetic alterations that enhance the efficacy of ATR and PARP inhibitor combinations while reducing toxicity through CRISPR screens and mechanistic analysis.

bioRxiv · Dec 13, 2021Cancer Biology

CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition

D. Gallo, J. T. F. Young, J. Fourtounis, G. Martino, A. Alvarez-Quilon, C. Bernier, N. M. Duffy, R. Papp, A. Roulston, R. Stocco, J. Szychowski, A. Veloso, H. Alam, P. S. Baruah, A. Bonneau Fortin, , D. Durocher

The paper identifies PKMYT1 as a therapeutic target for CCNE1-amplified cancers, showing that its inhibition leads to synthetic lethality and tumor regression in combination with gemcitabine.

bioRxiv · Apr 8, 2021Cancer Biology

CIP2A is a prime synthetic-lethal target for BRCA-mutated cancers

S. Adam, S. E. Rossi, N. Moatti, M. De Marco Zompit, T. F. Ng, A. Alvarez-Quilon, J. Desjardins, V. Bhaskaran, G. Martino, D. Setiaputra, S. M. Noordermeer, T. K. Ohsumi, N. Hustedt, R. K. Szilard, N. Chaudhary, , D. Durocher

The paper identifies CIP2A as a synthetic-lethal target in BRCA-mutated cancers by showing its essential role in mitotic chromosome stability and its interaction with TOPBP1.

bioRxiv · Feb 8, 2021 · PreprintCancer Biology